CASE Op-Ed in RealClearHealth: CMS Rule on Weight-Loss Drugs Would Reduce Healthcare Costs Along With Waistlines
As many well know, America has a persistent – and rising – epidemic of obesity. According to the Centers for...
CASE Op-Ed in DC Journal: Seniors Will Be Hurt by Medicare Advantage Marketing Rule
For decades, politicians like Vermont Senator Bernie Sanders have been calling for a national takeover of healthcare. Though this...
Biden Administration Gets its Way – American Healthcare Pays the Price
August 29, 2023 Today, the Centers for Medicare & Medicaid Services (CMS) released their list of the first 10...
Hospitals Support Transparency, Except When They Have To Be Transparent
August 16, 2019 Last month, The Centers for Medicare and Medicaid Services released a new proposal which will increase price...
The Problem With Price Caps: Why CMS Should Rethink Its Part B Proposal
This week, we submitted comments to Health and Human Services (HHS) Secretary Alex Azar, urging him to reevaluate and abandon...
CASE Op-Ed: Obamacare Hasn’t Helped Solve the Problem of Rehospitalization
Matthew Kandrach – President, CASE Feb 15, 2018, 7:00 AM – http://washex.am/2CmQ2jr Many Americans now pay more for their healthcare through increased out-of-pocket...
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/